Lumiera Health (TSXV:NHP.H) Days Payable: 165.19 (As of Aug. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Lumiera Health Days Payable?

Lumiera Health TSXV:NHP.H Days Payable is 165.19 as of Aug. 2023.

Lumiera Health's average Accounts Payable for the three months ended in Aug. 2023 was C$0.11 Mil. Lumiera Health's Cost of Goods Sold for the three months ended in Aug. 2023 was C$0.06 Mil. Hence, Lumiera Health's Days Payable for the three months ended in Aug. 2023 was 165.19.

The historical rank and industry rank for Lumiera Health's Days Payable or its related term are showing as below:

TSXV:NHP.H's Days Payable is not ranked *
in the Drug Manufacturers industry.
Industry Median: 90.38
* Ranked among companies with meaningful Days Payable only.

Lumiera Health's Days Payable increased from Aug. 2022 (132.62) to Aug. 2023 (165.19). It may suggest that Lumiera Health delayed paying its suppliers.

Lumiera Health Days Payable Historical Data

* Premium members only.

The historical data trend for Lumiera Health's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumiera Health Days Payable Chart

Lumiera Health Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Nov18 Nov19 Nov20 Nov21 Nov22
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 1,051.27 469.09 82.82

Lumiera Health Quarterly Data
Sep18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 132.62 41.70 1,140.63 168.02 165.19

TSXV:NHP.H vs ZTS, CTLT, VTRS: Days Payable Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lumiera Health's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lumiera Health Days Payable vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lumiera Health's Days Payable distribution charts can be found below:

* The bar in red indicates where Lumiera Health's Days Payable falls into.


Lumiera Health Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Lumiera Health's Days Payable for the fiscal year that ended in Nov. 2022 is calculated as

Days Payable (A: Nov. 2022 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Nov. 2021 ) + Accounts Payable (A: Nov. 2022 )) / count ) / Cost of Goods Sold (A: Nov. 2022 )*Days in Period
=( (0.069 + 0.152) / 2 ) / 0.487*365
=0.1105 / 0.487*365
=82.82

Lumiera Health's Days Payable for the quarter that ended in Aug. 2023 is calculated as:

Days Payable (Q: Aug. 2023 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: May. 2023 ) + Accounts Payable (Q: Aug. 2023 )) / count ) / Cost of Goods Sold (Q: Aug. 2023 )*Days in Period
=( (0.109 + 0.101) / 2 ) / 0.058*365 / 4
=0.105 / 0.058*365 / 4
=165.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 165.19 mean?
Lumiera Health (TSXV:NHP.H) has a Days Payable of 165.19 as of Aug. 2023. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lumiera Health and its competitors.
Is Lumiera Health's Days Payable too high?
Lumiera Health's current Days Payable is 165.19. The Drug Manufacturers industry median Days Payable is 90.38. Lumiera Health's value of 165.19 is 82.8% above this industry median.
How does Lumiera Health's Days Payable compare to ZTS and CTLT?
Lumiera Health's Days Payable of 165.19 can be compared against companies in the Drug Manufacturers industry. The industry median Days Payable is 90.38. Lumiera Health's value of 165.19 is 82.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumiera Health's current Days Payable of 165.19 is 82.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lumiera Health and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumiera Health's current Days Payable is 165.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumiera Health stock overvalued right now?
Lumiera Health (TSXV:NHP.H) has a current Days Payable of 165.19. The current Days Payable is 165.19 and 82.8% above the Drug Manufacturers industry median of 90.38. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Lumiera Health (TSXV:NHP.H), the current Days Payable is 165.19 as of Aug. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lumiera Health Business Description

Address 4500 Kimber, Suite 26, Saint-Hubert, QC, CAN, J3Y 8K5
Lumiera Health Inc operates as a product development, marketing and sales business of natural products that outsources the manufacturing of products to third-party manufacturing partners/suppliers. The company sells natural and homeopathic products as well as the development and commercialization of botanical-based products for low-risk agricultural use and human health care.